X linked News and Research

RSS

Google searches for 'death panels' trigger new ad war

Weeks after Sarah Palin coined the term, "death panels" to refer to a proposal in the House health reform bill, the term is among those helping to generate the most active internet advertising spree ever linked to a public policy issue, the Los Angeles Times reports.

5 Sep 2009

Insomnia increases blood pressure

Can't sleep at night? A new study published in the journal Sleep has found that people who suffer from insomnia have heightened nighttime blood pressure, which can lead to cardiac problems. The investigation, which measured the 24-hour blood pressure of insomniacs compared to sound sleepers, was conducted by researchers from the Universit- de Montr-al, its affiliated H-pital du Sacr--C-ur de Montr-al Sleep Disorders Centre and the Universit- Laval.

5 Sep 2009

Shire receives FDA approval for INTUNIV extended release tablets

Shire plc, the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.

4 Sep 2009

R'09 Conference to be held for improving the material usage and energy efficiency

Everyone will be thinking about energy efficiency and resource management in Davos from the 14th to the 16th September. The primary aim of the R'09 Conference, now being held for the ninth time, is to improve the material usage and energy efficiency of manufactured products, services and processes, whether during the production, usage or even the recycling phases.

4 Sep 2009

Shire's INTUNIV (Guanfacine) approved by the FDA for treatment of Attention-Deficit/Hyperactivity Disorder

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.

4 Sep 2009

Lawsuits filed against Johnson & Johnson, Ortho-McNeil Pharmaceutical and Walgreen

St. Louis-based law firm Carey & Danis LLC announces the filing of four civil lawsuits on behalf of twenty plaintiffs against Johnson & Johnson (NYSE: JNJ) and Ortho-McNeil Pharmaceutical Inc., the makers of the powerful antibiotic Levaquin, as well as the Walgreen Co. (NYSE:WAG), which sells the drug.

4 Sep 2009

Vaccinating women against HPV prevents breast cancer

Vaccinating women against the human papillomavirus (HPV) may prevent some forms of breast cancer and save tens of thousands of lives each year, new Australian research suggests.

4 Sep 2009

Genetic cause of progressive hearing loss discovered

A team led by scientists from The Scripps Research Institute has discovered a genetic cause of progressive hearing loss. The findings will help scientists better understand the nature of age-related decline in hearing and may lead to new therapies to prevent or treat the condition.

4 Sep 2009

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

Ten of ChemBridge's screening libraries available through CDD database

ChemBridge Corporation, a leading discovery chemistry company offering an extensive portfolio of discovery chemistry products and contract research services, has now made ten of their most popular screening libraries available to researchers via the Collaborative Drug Discovery (CDD) Public Access database.

3 Sep 2009

Green to Grow calls for support of the California Toxics-Free Babies and Toddlers Act

Green to Grow (www.greentogrow.com), a leading Los Angeles-based manufacturer of BPA-free baby bottles that provide a safe alternative to polycarbonate products containing Bisphenol A (BPA) - a chemical currently banned in Canada, Minnesota, Connecticut and under scrutiny in several European nations - is urging the public and California Assembly members to support the Toxics-Free Babies and Toddlers Act (SB 797).

3 Sep 2009

Researchers to analyse nanoparticles

Researchers at Swansea University's Centre for NanoHealth have been awarded £1 million by the Research Councils' Nanoscience through Engineering to Application cross-council programme, led by the Engineering and Physical Science Research Council (EPSRC), to analyse the levels at which nanoparticles can be deemed safe within cells.

3 Sep 2009

Vitamin C deficiency may impair mental development in newborn babies

New research at LIFE - Faculty of Life Sciences at University of Copenhagen shows that vitamin C deficiency may impair the mental development of new-born babies.

3 Sep 2009

New target for cancer cure identified

Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.

3 Sep 2009

Third-quarter fiscal 2009 results announced by Synovis Life Technologies

Synovis Life Technologies Reports Record Revenue Of $15 Million For The Third Quarter Of Fiscal 2009

2 Sep 2009

LINGO1 variant responsible for essential tremors and Parkinson's disease

Researchers at the Mayo Clinic campus in Florida and their collaborators worldwide have discovered that a single gene promotes development of essential tremor in some patients and Parkinson's disease in others.

2 Sep 2009

Rapid progression of multiple sclerosis linked to smoking

Patients with multiple sclerosis who smoke appear to experience a more rapid progression of their disease, according to a report in the July issue of Archives of Neurology, one of the JAMA/Archives journals.

2 Sep 2009

GE Healthcare to develop wireless medical monitoring systems for patient care

In what would represent an important step forward in revolutionizing the way patients are monitored in the future, GE announced an initiative aimed to develop wireless medical monitoring systems, or body sensor networks (BSN), which would replace the traditional tangle of bedside cables used to capture a patient’s vital signs. GE’s vision for the systems would enable wireless monitoring from anywhere in the hospital—or even remotely from home.

2 Sep 2009

JAMA study reveals the genetic signature of brain cancer

A pair of studies in the July 15 issue of the Journal of the American Medical Association (JAMA) spell out how much closer science has come to unraveling the genetic signature of brain cancer, according to a researcher at the University of Alabama at Birmingham (UAB). Boris Pasche, M.D., Ph.D., director of the UAB Division of Hematology and Oncology, believes these studies represent a new vanguard in the still-changing field of DNA analysis.

2 Sep 2009

Weight gain in men linked with risk of prostate cancer

Body mass in younger and older adulthood, and weight gain between these periods of life, may influence a man's risk for prostate cancer. This risk varies among different ethnic populations, according to results of a study in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

2 Sep 2009